Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer

Table 1 Details of response-differentially methylated regions (response-DMRs)

Gene ID	Chr	Range (hg19)	Average Δβ (%)^α	No. CpGs	P^β	CpG Island % (Island/Shore)	RefSeq % (Promoter/Exon)	MCF7 ChromHMM % (Active/Bivalent/Polycomb/Quiescent)^γ
TMEM176A/B	Chr7	150,497,065–150,498,205	27.2	14	2.04 × 10⁻⁹	100/0	90/10	0/0/0/100
UNC5D	Chr8	3,509,283–35,093,411	28.2	10	2.35 × 10⁻⁴	100/0	93/7	0/0/100/0
STAC2	Chr17	37,381,830–37,382,301	14.9	7	3.73 × 10⁻⁴	100/0	72/28	0/0/0/100
SDR42E1	Chr16	82,044,738–82,045,297	23.8	10	1.13 × 10⁻³	80/20	90/10	100/0/0/0
NELL1	Chr11	20,690,682–20,691,429	22.8	12	1.49 × 10⁻³	100/0	83/17	0/0/100/0
GRP	Chr18	56,887,002–56,887,785	20.3	11	2.97 × 10⁻³	73/27	73/27	0/0/100/0
FOXG1	Chr14	29,235,928–29,236,535	17.5	11	2.00 × 10⁻²	0/100	73/27	0/0/100/0
CDH8	Chr16	62,069,806–62,070,365	24.2	10	2.00 × 10⁻²	100/0	100/0	0/10/90/0
GRIA4	Chr11	105,480,979–105,481,322	15.4	7	2.26 × 10⁻¹	86/14	86/14	0/0/100/0

ISSN: 1868-7083